Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amarin Corporation PLC Shares Fall On FDA Review Of Vascepa Combination Therapy-Reuters


Friday, 11 Oct 2013 05:27pm EDT 

Reuters reported that Amarin Corporation PLC share fell on Friday on concerns the U.S. Food and Drug Administration will reject its application to market Vascepa, a drug that lowers blood fat levels, to a broader patient population. Staff reviewers for the FDA posted their assessment of Amarin's application on the agency's website on Friday, and some analysts said the review appeared more cautious than they had expected. Vascepa is currently approved as a stand-alone treatment to lower high levels of triglycerides, or blood fats, which can raise the risk of heart disease. 

Related Company News

Company Quote

1.05
-0.0050 -0.47%
23 Oct 2014